FDA Rebuffs Allergan On Generic Restasis Tests
The U.S. Food and Drug Administration has rejected Allergan's latest attack on its standards for generic versions of dry-eye blockbuster Restasis, asserting "clear legal authority" to approve copycats that aren't tested...To view the full article, register now.
Already a subscriber? Click here to view full article